BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

The stock's fall snapped a five-day winning streak.

When your first film is "Hiroshima Mon Amour" or "Eraserhead" it sets an impossibly high bar - but these directors reached it ...

Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on ...